<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244984</url>
  </required_header>
  <id_info>
    <org_study_id>113989</org_study_id>
    <nct_id>NCT01244984</nct_id>
  </id_info>
  <brief_title>A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma</brief_title>
  <official_title>A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to assess the safety and tolerability of 52-week teatment
      with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder
      once-daily in Japanese adult subjects with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)</measure>
    <time_frame>From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold &gt;=5%) and SAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD</measure>
    <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 24-hour Urinary Cortisol Excretion</measure>
    <time_frame>Baseline (Week 0), Week 24, and Week 52/WD</time_frame>
    <description>Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline (Week 0), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate (HR)</measure>
    <time_frame>Baseline (Week 0), Week 12, Week 24, and Week 52/WD</time_frame>
    <description>Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Week 12, Week 24, and Week 52/WD</time_frame>
    <description>A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline[Week -2], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Asthma Exacerbation During the Study Treatment</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Symptom Score During the Study Treatment</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Percentage of Rescue-free 24-hour Periods</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Rescue Medication Inhalations</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone Furoate/GW642444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination inhaled corticosteroid and long-acting beta2-agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Furoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled corticosteroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Furoate/GW642444 Inhalation Powder</intervention_name>
    <description>Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks</description>
    <arm_group_label>Fluticasone Furoate/GW642444</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Furoate Inhalation Powder</intervention_name>
    <description>Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks</description>
    <arm_group_label>Fluticasone Furoate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out patient at least 18 years of age

          -  Both genderds; females of childbearing potential must be willing to use birth control
             method

          -  A diagnosis of asthma at least 6 months prior to Screening

          -  A best FEV1 of at least 50% of the predicted nomal value at Screening

          -  Subjects have been receiving maintanance therapy for asthma, for at least 4 weeks
             prior to Screening

        Exclusion Criteria:

          -  History of life-threating asthma

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation within 12 weeks

          -  Concurrent respiratory disease or other disease that would confound study
             participation or affect subject safety

          -  Allergies to study drugs, study drugs7 excipients, medications related to study drugs

          -  Taking another investigational medication or medication prohibited for use during this
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>277-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>501-6062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>373-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0844</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>732-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>739-0402</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>665-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>670-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>253-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>601-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8087</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>983-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagano</city>
        <zip>390-0303</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagano</city>
        <zip>390-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-0862</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>714-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>569-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>105-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>134-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>185-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toyama</city>
        <zip>937-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <results_first_submitted>June 6, 2013</results_first_submitted>
  <results_first_submitted_qc>June 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2013</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>Fluticasone furoate</keyword>
  <keyword>GW642444</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113989</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Following screening (Visit1) and a 2-week Run-in Period during which participants continued to use their respective asthma therapy at a fixed dose. Participants who met continuation criteria at the end of Run-in Period (Visit 2) were allocated to a 52-Week Treatment Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FF/GW642444 100/25 µg</title>
          <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg ) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
        </group>
        <group group_id="P2">
          <title>FF/GW642444 200/25 µg</title>
          <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
        </group>
        <group group_id="P3">
          <title>FF 100 µg</title>
          <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FF/GW642444 100/25 µg</title>
          <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
        </group>
        <group group_id="B2">
          <title>FF/GW642444 200/25 µg</title>
          <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
        </group>
        <group group_id="B3">
          <title>FF 100 µg</title>
          <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="13.74"/>
                    <measurement group_id="B2" value="52.6" spread="15.05"/>
                    <measurement group_id="B3" value="46.8" spread="15.46"/>
                    <measurement group_id="B4" value="50.1" spread="15.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold &gt;=5%) and SAE.</description>
        <time_frame>From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who had been randomized to and received at least one dose of randomized medication in the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold &gt;=5%) and SAE.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who had been randomized to and received at least one dose of randomized medication in the treatment period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, Baseline, n=60,93,90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.509"/>
                    <measurement group_id="O2" value="0.71" spread="0.419"/>
                    <measurement group_id="O3" value="0.79" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.473"/>
                    <measurement group_id="O2" value="0.67" spread="0.414"/>
                    <measurement group_id="O3" value="0.79" spread="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.510"/>
                    <measurement group_id="O2" value="0.66" spread="0.392"/>
                    <measurement group_id="O3" value="0.72" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.510"/>
                    <measurement group_id="O2" value="0.64" spread="0.383"/>
                    <measurement group_id="O3" value="0.72" spread="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Baseline, n=60,93,90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="4.476"/>
                    <measurement group_id="O2" value="5.03" spread="3.843"/>
                    <measurement group_id="O3" value="5.32" spread="3.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="3.257"/>
                    <measurement group_id="O2" value="4.01" spread="3.112"/>
                    <measurement group_id="O3" value="4.90" spread="3.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="3.678"/>
                    <measurement group_id="O2" value="4.00" spread="2.753"/>
                    <measurement group_id="O3" value="4.37" spread="3.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="3.981"/>
                    <measurement group_id="O2" value="4.27" spread="3.247"/>
                    <measurement group_id="O3" value="4.60" spread="3.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.49" spread="5.948"/>
                    <measurement group_id="O2" value="30.95" spread="7.504"/>
                    <measurement group_id="O3" value="31.26" spread="6.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.22" spread="6.891"/>
                    <measurement group_id="O2" value="29.15" spread="6.378"/>
                    <measurement group_id="O3" value="29.35" spread="7.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes , Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.06" spread="6.269"/>
                    <measurement group_id="O2" value="28.40" spread="6.282"/>
                    <measurement group_id="O3" value="28.83" spread="6.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.01" spread="6.702"/>
                    <measurement group_id="O2" value="27.67" spread="7.913"/>
                    <measurement group_id="O3" value="29.04" spread="7.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Baseline, n=60,93,90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="1.307"/>
                    <measurement group_id="O2" value="5.39" spread="1.408"/>
                    <measurement group_id="O3" value="5.35" spread="1.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="1.187"/>
                    <measurement group_id="O2" value="5.61" spread="1.626"/>
                    <measurement group_id="O3" value="5.65" spread="1.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="1.571"/>
                    <measurement group_id="O2" value="5.52" spread="1.321"/>
                    <measurement group_id="O3" value="5.41" spread="1.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="1.637"/>
                    <measurement group_id="O2" value="5.72" spread="1.366"/>
                    <measurement group_id="O3" value="5.59" spread="1.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Baseline, n=60,93,90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.91" spread="8.064"/>
                    <measurement group_id="O2" value="57.92" spread="8.103"/>
                    <measurement group_id="O3" value="57.28" spread="7.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.14" spread="7.785"/>
                    <measurement group_id="O2" value="60.57" spread="7.474"/>
                    <measurement group_id="O3" value="59.31" spread="8.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.82" spread="7.893"/>
                    <measurement group_id="O2" value="61.37" spread="6.790"/>
                    <measurement group_id="O3" value="60.64" spread="7.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.54" spread="8.910"/>
                    <measurement group_id="O2" value="61.70" spread="8.326"/>
                    <measurement group_id="O3" value="60.05" spread="7.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>10^9 per liter (Gi/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eosinophils, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.338" spread="0.2514"/>
                    <measurement group_id="O2" value="0.323" spread="0.2591"/>
                    <measurement group_id="O3" value="0.323" spread="0.2042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.306" spread="0.2106"/>
                    <measurement group_id="O2" value="0.245" spread="0.2057"/>
                    <measurement group_id="O3" value="0.286" spread="0.2154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.282" spread="0.2244"/>
                    <measurement group_id="O2" value="0.247" spread="0.1864"/>
                    <measurement group_id="O3" value="0.256" spread="0.1907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" spread="0.2399"/>
                    <measurement group_id="O2" value="0.281" spread="0.2332"/>
                    <measurement group_id="O3" value="0.285" spread="0.2032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.4" spread="53.41"/>
                    <measurement group_id="O2" value="257.1" spread="64.98"/>
                    <measurement group_id="O3" value="254.1" spread="60.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.9" spread="62.25"/>
                    <measurement group_id="O2" value="269.3" spread="60.55"/>
                    <measurement group_id="O3" value="259.0" spread="54.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.1" spread="62.25"/>
                    <measurement group_id="O2" value="270.2" spread="66.60"/>
                    <measurement group_id="O3" value="260.1" spread="58.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.2" spread="54.93"/>
                    <measurement group_id="O2" value="276.7" spread="68.64"/>
                    <measurement group_id="O3" value="270.3" spread="63.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="1.716"/>
                    <measurement group_id="O2" value="6.39" spread="1.503"/>
                    <measurement group_id="O3" value="6.13" spread="1.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.90" spread="1.642"/>
                    <measurement group_id="O2" value="6.11" spread="1.462"/>
                    <measurement group_id="O3" value="5.95" spread="1.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="1.541"/>
                    <measurement group_id="O2" value="6.19" spread="1.743"/>
                    <measurement group_id="O3" value="6.01" spread="1.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="1.625"/>
                    <measurement group_id="O2" value="6.45" spread="1.530"/>
                    <measurement group_id="O3" value="6.24" spread="1.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.661" spread="1.3444"/>
                    <measurement group_id="O2" value="3.734" spread="1.2446"/>
                    <measurement group_id="O3" value="3.536" spread="1.1080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.522" spread="1.2140"/>
                    <measurement group_id="O2" value="3.729" spread="1.1131"/>
                    <measurement group_id="O3" value="3.567" spread="1.2419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.522" spread="1.1186"/>
                    <measurement group_id="O2" value="3.833" spread="1.2812"/>
                    <measurement group_id="O3" value="3.690" spread="1.2837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.585" spread="1.2570"/>
                    <measurement group_id="O2" value="4.010" spread="1.2422"/>
                    <measurement group_id="O3" value="3.795" spread="1.2221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.7" spread="15.88"/>
                    <measurement group_id="O2" value="141.1" spread="16.34"/>
                    <measurement group_id="O3" value="138.6" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="15.10"/>
                    <measurement group_id="O2" value="140.6" spread="15.58"/>
                    <measurement group_id="O3" value="139.1" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.4" spread="15.45"/>
                    <measurement group_id="O2" value="140.8" spread="15.99"/>
                    <measurement group_id="O3" value="139.0" spread="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.4" spread="14.16"/>
                    <measurement group_id="O2" value="139.0" spread="15.91"/>
                    <measurement group_id="O3" value="136.7" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Proportions of I</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4214" spread="0.04429"/>
                    <measurement group_id="O2" value="0.4374" spread="0.04417"/>
                    <measurement group_id="O3" value="0.4319" spread="0.04090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4288" spread="0.04224"/>
                    <measurement group_id="O2" value="0.4325" spread="0.04199"/>
                    <measurement group_id="O3" value="0.4283" spread="0.03870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4238" spread="0.04228"/>
                    <measurement group_id="O2" value="0.4333" spread="0.04277"/>
                    <measurement group_id="O3" value="0.4288" spread="0.03858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4194" spread="0.03921"/>
                    <measurement group_id="O2" value="0.4272" spread="0.04367"/>
                    <measurement group_id="O3" value="0.4215" spread="0.04138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>10^12 per liter (Ti/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.557" spread="0.4987"/>
                    <measurement group_id="O2" value="4.714" spread="0.4804"/>
                    <measurement group_id="O3" value="4.689" spread="0.4493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.656" spread="0.4540"/>
                    <measurement group_id="O2" value="4.685" spread="0.4888"/>
                    <measurement group_id="O3" value="4.696" spread="0.4267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.626" spread="0.4679"/>
                    <measurement group_id="O2" value="4.687" spread="0.4898"/>
                    <measurement group_id="O3" value="4.681" spread="0.4357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.603" spread="0.4469"/>
                    <measurement group_id="O2" value="4.671" spread="0.5082"/>
                    <measurement group_id="O3" value="4.664" spread="0.4643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="2.72"/>
                    <measurement group_id="O2" value="44.8" spread="2.59"/>
                    <measurement group_id="O3" value="44.7" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="2.37"/>
                    <measurement group_id="O2" value="44.1" spread="2.66"/>
                    <measurement group_id="O3" value="44.3" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="2.52"/>
                    <measurement group_id="O2" value="43.9" spread="2.67"/>
                    <measurement group_id="O3" value="43.7" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="2.49"/>
                    <measurement group_id="O2" value="43.4" spread="3.03"/>
                    <measurement group_id="O3" value="43.8" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="4.36"/>
                    <measurement group_id="O2" value="73.6" spread="3.62"/>
                    <measurement group_id="O3" value="74.6" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="3.70"/>
                    <measurement group_id="O2" value="73.0" spread="3.83"/>
                    <measurement group_id="O3" value="74.4" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="4.49"/>
                    <measurement group_id="O2" value="72.4" spread="3.92"/>
                    <measurement group_id="O3" value="73.3" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="3.55"/>
                    <measurement group_id="O2" value="71.4" spread="3.60"/>
                    <measurement group_id="O3" value="72.5" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>International unit per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AP, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.9" spread="57.34"/>
                    <measurement group_id="O2" value="222.7" spread="62.97"/>
                    <measurement group_id="O3" value="217.1" spread="64.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.9" spread="56.39"/>
                    <measurement group_id="O2" value="214.9" spread="56.73"/>
                    <measurement group_id="O3" value="220.3" spread="59.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.3" spread="59.48"/>
                    <measurement group_id="O2" value="216.4" spread="57.33"/>
                    <measurement group_id="O3" value="215.9" spread="58.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.1" spread="64.76"/>
                    <measurement group_id="O2" value="219.9" spread="60.27"/>
                    <measurement group_id="O3" value="217.0" spread="57.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="9.69"/>
                    <measurement group_id="O2" value="22.3" spread="14.46"/>
                    <measurement group_id="O3" value="21.9" spread="16.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="23.12"/>
                    <measurement group_id="O2" value="21.3" spread="11.39"/>
                    <measurement group_id="O3" value="20.7" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="11.52"/>
                    <measurement group_id="O2" value="20.7" spread="10.45"/>
                    <measurement group_id="O3" value="20.1" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="12.46"/>
                    <measurement group_id="O2" value="23.2" spread="13.52"/>
                    <measurement group_id="O3" value="23.0" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="5.48"/>
                    <measurement group_id="O2" value="22.0" spread="7.50"/>
                    <measurement group_id="O3" value="21.5" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="10.08"/>
                    <measurement group_id="O2" value="22.0" spread="7.59"/>
                    <measurement group_id="O3" value="21.7" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="5.72"/>
                    <measurement group_id="O2" value="21.2" spread="7.29"/>
                    <measurement group_id="O3" value="20.6" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="9.47"/>
                    <measurement group_id="O2" value="23.3" spread="7.53"/>
                    <measurement group_id="O3" value="22.8" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.9" spread="56.95"/>
                    <measurement group_id="O2" value="149.8" spread="134.73"/>
                    <measurement group_id="O3" value="104.0" spread="45.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" spread="84.32"/>
                    <measurement group_id="O2" value="134.0" spread="114.92"/>
                    <measurement group_id="O3" value="97.4" spread="39.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.4" spread="77.09"/>
                    <measurement group_id="O2" value="131.9" spread="118.86"/>
                    <measurement group_id="O3" value="103.0" spread="58.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.3" spread="48.78"/>
                    <measurement group_id="O2" value="126.6" spread="105.24"/>
                    <measurement group_id="O3" value="99.9" spread="48.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="14.04"/>
                    <measurement group_id="O2" value="34.9" spread="42.70"/>
                    <measurement group_id="O3" value="30.0" spread="28.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="15.29"/>
                    <measurement group_id="O2" value="31.0" spread="32.21"/>
                    <measurement group_id="O3" value="28.2" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="14.73"/>
                    <measurement group_id="O2" value="30.8" spread="39.66"/>
                    <measurement group_id="O3" value="26.5" spread="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="16.85"/>
                    <measurement group_id="O2" value="34.6" spread="48.03"/>
                    <measurement group_id="O3" value="28.9" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.7" spread="23.78"/>
                    <measurement group_id="O2" value="186.9" spread="34.40"/>
                    <measurement group_id="O3" value="175.3" spread="27.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.8" spread="32.66"/>
                    <measurement group_id="O2" value="185.7" spread="37.83"/>
                    <measurement group_id="O3" value="175.1" spread="28.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.3" spread="29.35"/>
                    <measurement group_id="O2" value="184.4" spread="36.45"/>
                    <measurement group_id="O3" value="174.3" spread="27.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.5" spread="31.50"/>
                    <measurement group_id="O2" value="188.1" spread="39.96"/>
                    <measurement group_id="O3" value="177.9" spread="29.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Micromoles per Liter (µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>direct [BD], Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.220" spread="1.4459"/>
                    <measurement group_id="O2" value="3.236" spread="1.5838"/>
                    <measurement group_id="O3" value="3.401" spread="1.7851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>direct [BD], Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.948" spread="1.2729"/>
                    <measurement group_id="O2" value="3.230" spread="1.5475"/>
                    <measurement group_id="O3" value="3.125" spread="1.6535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>direct [BD], Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.214" spread="1.5717"/>
                    <measurement group_id="O2" value="3.338" spread="1.8484"/>
                    <measurement group_id="O3" value="2.903" spread="1.5970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>direct [BD], Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.850" spread="1.2057"/>
                    <measurement group_id="O2" value="3.344" spread="1.5574"/>
                    <measurement group_id="O3" value="3.055" spread="1.5569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>indirect [BI], Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.495" spread="2.9883"/>
                    <measurement group_id="O2" value="7.079" spread="3.3788"/>
                    <measurement group_id="O3" value="7.125" spread="2.8688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>indirect [BI], Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.017" spread="3.1004"/>
                    <measurement group_id="O2" value="7.600" spread="3.2131"/>
                    <measurement group_id="O3" value="6.938" spread="3.0451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>indirect [BI], Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.842" spread="5.1553"/>
                    <measurement group_id="O2" value="7.747" spread="3.7420"/>
                    <measurement group_id="O3" value="6.760" spread="3.2222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>indirect [BI], Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.640" spread="2.7100"/>
                    <measurement group_id="O2" value="7.505" spread="3.5676"/>
                    <measurement group_id="O3" value="6.936" spread="3.4525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total [BT], Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.716" spread="4.1989"/>
                    <measurement group_id="O2" value="10.315" spread="4.7735"/>
                    <measurement group_id="O3" value="10.526" spread="4.3571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total [BT], Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.965" spread="4.1781"/>
                    <measurement group_id="O2" value="10.830" spread="4.5424"/>
                    <measurement group_id="O3" value="10.063" spread="4.3902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total [BT], Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.056" spread="6.4954"/>
                    <measurement group_id="O2" value="11.084" spread="5.4427"/>
                    <measurement group_id="O3" value="9.663" spread="4.4958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total [BT], Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.491" spread="3.6503"/>
                    <measurement group_id="O2" value="10.849" spread="4.8513"/>
                    <measurement group_id="O3" value="9.991" spread="4.7177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8800" spread="13.37091"/>
                    <measurement group_id="O2" value="66.4806" spread="15.94483"/>
                    <measurement group_id="O3" value="62.0568" spread="12.65536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3042" spread="13.92743"/>
                    <measurement group_id="O2" value="62.9408" spread="15.71444"/>
                    <measurement group_id="O3" value="60.1628" spread="13.02866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7614" spread="12.91371"/>
                    <measurement group_id="O2" value="64.5213" spread="15.90631"/>
                    <measurement group_id="O3" value="60.6773" spread="13.02242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4067" spread="12.52458"/>
                    <measurement group_id="O2" value="64.6204" spread="16.01762"/>
                    <measurement group_id="O3" value="61.3536" spread="14.38660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.0419" spread="90.67062"/>
                    <measurement group_id="O2" value="305.7784" spread="78.88104"/>
                    <measurement group_id="O3" value="310.6178" spread="96.11471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.6301" spread="86.10161"/>
                    <measurement group_id="O2" value="301.6297" spread="74.72395"/>
                    <measurement group_id="O3" value="303.8266" spread="87.04586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.6561" spread="78.45023"/>
                    <measurement group_id="O2" value="310.8726" spread="86.38513"/>
                    <measurement group_id="O3" value="308.5352" spread="91.73313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.2315" spread="78.61596"/>
                    <measurement group_id="O2" value="300.3079" spread="82.30325"/>
                    <measurement group_id="O3" value="308.0262" spread="92.43123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chloride, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="1.97"/>
                    <measurement group_id="O2" value="104.2" spread="1.85"/>
                    <measurement group_id="O3" value="103.6" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.9" spread="2.05"/>
                    <measurement group_id="O2" value="105.6" spread="2.38"/>
                    <measurement group_id="O3" value="105.6" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.4" spread="2.04"/>
                    <measurement group_id="O2" value="105.0" spread="2.44"/>
                    <measurement group_id="O3" value="105.0" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.6" spread="2.19"/>
                    <measurement group_id="O2" value="105.3" spread="2.41"/>
                    <measurement group_id="O3" value="104.8" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/Bicarbonate, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="2.02"/>
                    <measurement group_id="O2" value="25.0" spread="1.84"/>
                    <measurement group_id="O3" value="25.2" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/Bicarbonate, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="2.01"/>
                    <measurement group_id="O2" value="24.8" spread="2.13"/>
                    <measurement group_id="O3" value="25.4" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/Bicarbonate, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="2.26"/>
                    <measurement group_id="O2" value="25.3" spread="2.33"/>
                    <measurement group_id="O3" value="24.8" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/Bicarbonate, Week 52/WD, n=60, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="2.03"/>
                    <measurement group_id="O2" value="25.3" spread="2.14"/>
                    <measurement group_id="O3" value="25.1" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6685" spread="0.88699"/>
                    <measurement group_id="O2" value="5.7826" spread="0.98753"/>
                    <measurement group_id="O3" value="5.7669" spread="1.03176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5606" spread="1.07679"/>
                    <measurement group_id="O2" value="5.7848" spread="1.01409"/>
                    <measurement group_id="O3" value="5.7647" spread="1.05233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8228" spread="1.41235"/>
                    <measurement group_id="O2" value="5.8593" spread="0.97613"/>
                    <measurement group_id="O3" value="5.8169" spread="1.43353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4455" spread="1.05905"/>
                    <measurement group_id="O2" value="5.7743" spread="1.00636"/>
                    <measurement group_id="O3" value="5.8572" spread="1.17153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="0.279"/>
                    <measurement group_id="O2" value="4.13" spread="0.332"/>
                    <measurement group_id="O3" value="4.12" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="0.282"/>
                    <measurement group_id="O2" value="4.17" spread="0.366"/>
                    <measurement group_id="O3" value="4.16" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="0.326"/>
                    <measurement group_id="O2" value="4.17" spread="0.390"/>
                    <measurement group_id="O3" value="4.16" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="0.333"/>
                    <measurement group_id="O2" value="4.17" spread="0.363"/>
                    <measurement group_id="O3" value="4.16" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.2" spread="1.53"/>
                    <measurement group_id="O2" value="141.3" spread="1.66"/>
                    <measurement group_id="O3" value="140.7" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.1" spread="1.62"/>
                    <measurement group_id="O2" value="140.7" spread="1.81"/>
                    <measurement group_id="O3" value="140.8" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.9" spread="1.23"/>
                    <measurement group_id="O2" value="141.1" spread="1.89"/>
                    <measurement group_id="O3" value="141.0" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.3" spread="1.42"/>
                    <measurement group_id="O2" value="141.6" spread="1.62"/>
                    <measurement group_id="O3" value="141.2" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0658" spread="1.50071"/>
                    <measurement group_id="O2" value="5.0928" spread="1.38695"/>
                    <measurement group_id="O3" value="4.7116" spread="1.12591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0792" spread="1.18333"/>
                    <measurement group_id="O2" value="4.9865" spread="1.23302"/>
                    <measurement group_id="O3" value="4.7973" spread="1.37172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0177" spread="1.16880"/>
                    <measurement group_id="O2" value="4.9593" spread="1.23301"/>
                    <measurement group_id="O3" value="4.8510" spread="1.24616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9932" spread="1.28828"/>
                    <measurement group_id="O2" value="4.9869" spread="1.41120"/>
                    <measurement group_id="O3" value="4.7120" spread="1.16694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine pH, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="0.774"/>
                    <measurement group_id="O2" value="6.36" spread="0.883"/>
                    <measurement group_id="O3" value="6.46" spread="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41" spread="0.726"/>
                    <measurement group_id="O2" value="6.36" spread="0.798"/>
                    <measurement group_id="O3" value="6.39" spread="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="0.785"/>
                    <measurement group_id="O2" value="6.40" spread="0.878"/>
                    <measurement group_id="O3" value="6.33" spread="0.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="0.795"/>
                    <measurement group_id="O2" value="6.50" spread="0.775"/>
                    <measurement group_id="O3" value="6.42" spread="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
        <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD</title>
          <description>Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>ratio of urine density to water density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine Specific Gravity, Baseline, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0177" spread="0.00764"/>
                    <measurement group_id="O2" value="1.0177" spread="0.00830"/>
                    <measurement group_id="O3" value="1.0173" spread="0.00734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Specific Gravity, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0171" spread="0.00731"/>
                    <measurement group_id="O2" value="1.0167" spread="0.00789"/>
                    <measurement group_id="O3" value="1.0163" spread="0.00806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Specific Gravity, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0174" spread="0.00795"/>
                    <measurement group_id="O2" value="1.0180" spread="0.00755"/>
                    <measurement group_id="O3" value="1.0179" spread="0.00758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Specific Gravity, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0160" spread="0.00689"/>
                    <measurement group_id="O2" value="1.0159" spread="0.00755"/>
                    <measurement group_id="O3" value="1.0156" spread="0.00811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD</title>
        <description>Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.</description>
        <time_frame>Baseline (Week -2), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD</title>
          <description>Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.</description>
          <population>ITT Population. Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UOB, Neg, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, TRA, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 1+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 2+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 3+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, Neg, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, TRA, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 1+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 2+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 3+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, Neg, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, TRA, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 1+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 2+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 3+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, Neg, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, TRA, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 1+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 2+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UOB, 3+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, Neg, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, TRA, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 1+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 2+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 3+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, Neg, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, TRA, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 1+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 2+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 3+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, Neg, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, TRA, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 1+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 2+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 3+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, Neg, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, TRA, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 1+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 2+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UG, 3+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, Neg, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, TRA, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 1+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 2+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 3+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, Neg, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, TRA, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 1+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 2+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 3+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, Neg, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, TRA, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 1+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 2+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 3+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, Neg, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, TRA, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 1+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 2+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK, 3+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, Neg, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, TRA, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 1+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 2+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 3+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, Neg, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, TRA, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 1+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 2+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 3+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, Neg, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, TRA, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 1+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 2+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 3+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, Neg, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, TRA, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 1+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 2+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UP, 3+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC, Neg, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,TRA, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,1+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,2+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,3+, BL, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,Neg, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,TRA, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,1+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,2+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,3+, Week 12, n=58, 90, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,Neg, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,TRA, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,1+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,2+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,3+, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,Neg, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,TRA, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,1+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,2+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UWBC,3+, Week 52/WD, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 24-hour Urinary Cortisol Excretion</title>
        <description>Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline (Week 0), Week 24, and Week 52/WD</time_frame>
        <population>Urine cortisol (UC) Population: all participants in the ITT Population from whom urine specimens were collected and who were considered not to have any confounding factors that might affect the analysis of the results of the specimens. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-hour Urinary Cortisol Excretion</title>
          <description>Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.</description>
          <population>Urine cortisol (UC) Population: all participants in the ITT Population from whom urine specimens were collected and who were considered not to have any confounding factors that might affect the analysis of the results of the specimens. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
          <units>Nanomoles (nmol)/24 hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, n=19, 20, 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0218" spread="42.309"/>
                    <measurement group_id="O2" value="1.0602" spread="64.825"/>
                    <measurement group_id="O3" value="0.9698" spread="67.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, n=18, 19, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8956" spread="48.231"/>
                    <measurement group_id="O2" value="1.0802" spread="73.912"/>
                    <measurement group_id="O3" value="0.8190" spread="41.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure</title>
        <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline (Week 0), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure</title>
          <description>Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Week 12, n=58, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="9.54"/>
                    <measurement group_id="O2" value="1.2" spread="11.42"/>
                    <measurement group_id="O3" value="0.7" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="11.76"/>
                    <measurement group_id="O2" value="-1.6" spread="12.88"/>
                    <measurement group_id="O3" value="0.1" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Week 52/WD, n=60, 92, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="9.34"/>
                    <measurement group_id="O2" value="0.5" spread="11.95"/>
                    <measurement group_id="O3" value="0.9" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 12, n=58, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.09"/>
                    <measurement group_id="O2" value="1.0" spread="8.63"/>
                    <measurement group_id="O3" value="-2.3" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.46"/>
                    <measurement group_id="O2" value="0.5" spread="9.43"/>
                    <measurement group_id="O3" value="-1.1" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Week 52/WD, n=60, 92, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="8.55"/>
                    <measurement group_id="O2" value="1.5" spread="10.13"/>
                    <measurement group_id="O3" value="-0.1" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate (HR)</title>
        <description>Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline (Week 0), Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate (HR)</title>
          <description>Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Only those participants with post-Baseline data available at the indicated time points were analyzed.</population>
          <units>Beats/Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=58, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="12.27"/>
                    <measurement group_id="O2" value="-0.6" spread="9.02"/>
                    <measurement group_id="O3" value="1.3" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="9.24"/>
                    <measurement group_id="O2" value="0.1" spread="9.18"/>
                    <measurement group_id="O3" value="1.1" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, n=60, 92, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="10.91"/>
                    <measurement group_id="O2" value="-1.4" spread="9.62"/>
                    <measurement group_id="O3" value="1.1" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings</title>
        <description>A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline[Week -2], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.</description>
        <time_frame>Week 12, Week 24, and Week 52/WD</time_frame>
        <population>ITT Population. . Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings</title>
          <description>A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline[Week -2], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.</description>
          <population>ITT Population. . Only participants remaining in the study and contributing evaluable data at the indicated time points were analyzed.; thus the number of participants analyzed reflects everyone in the ITT Population. The number of participants assessed for each parameter is indicated by &quot;n=X, X&quot;.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Abn NCS, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Abn CS, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Abn NCS, n=58, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Abn CS, n=58, 90, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Abn NCS, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Abn CS, n=58, 83, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, Abn NCS, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/WD, Abn CS, n=60, 90, 89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Asthma Exacerbation During the Study Treatment</title>
        <description>A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Asthma Exacerbation During the Study Treatment</title>
          <description>A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment</title>
        <description>Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment</title>
          <description>Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.</description>
          <population>ITT Population</population>
          <units>Litres per Minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEF AM, Week 0-52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.29" spread="36.304"/>
                    <measurement group_id="O2" value="23.98" spread="38.668"/>
                    <measurement group_id="O3" value="12.38" spread="32.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PEF PM, Week 0-52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.23" spread="35.274"/>
                    <measurement group_id="O2" value="26.29" spread="40.510"/>
                    <measurement group_id="O3" value="15.64" spread="30.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Symptom Score During the Study Treatment</title>
        <description>The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Symptom Score During the Study Treatment</title>
          <description>The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.638"/>
                    <measurement group_id="O2" value="-0.14" spread="0.856"/>
                    <measurement group_id="O3" value="-0.19" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment</title>
        <description>Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment</title>
          <description>Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
          <population>ITT Population</population>
          <units>Percentage of symptom-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="20.382"/>
                    <measurement group_id="O2" value="6.51" spread="28.290"/>
                    <measurement group_id="O3" value="8.19" spread="26.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Percentage of Rescue-free 24-hour Periods</title>
        <description>The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Percentage of Rescue-free 24-hour Periods</title>
          <description>The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.</description>
          <population>ITT Population</population>
          <units>Percentage of rescue free 24-hour period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-12, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.94" spread="9.553"/>
                    <measurement group_id="O2" value="95.51" spread="16.427"/>
                    <measurement group_id="O3" value="92.79" spread="17.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-24, n=58, 91, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.60" spread="7.521"/>
                    <measurement group_id="O2" value="95.94" spread="13.477"/>
                    <measurement group_id="O3" value="94.35" spread="16.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-36, n=58, 84, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.99" spread="8.757"/>
                    <measurement group_id="O2" value="95.24" spread="14.685"/>
                    <measurement group_id="O3" value="94.14" spread="15.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-52, n=57, 79, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.38" spread="7.253"/>
                    <measurement group_id="O2" value="95.71" spread="13.382"/>
                    <measurement group_id="O3" value="95.13" spread="14.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-52, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.01" spread="7.736"/>
                    <measurement group_id="O2" value="95.76" spread="13.556"/>
                    <measurement group_id="O3" value="94.28" spread="15.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Rescue Medication Inhalations</title>
        <description>Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>ITT Population. The number of participants analyzed depends on the number of participants remaining in the indaicated time period.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/GW642444 100/25 µg</title>
            <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>FF/GW642444 200/25 µg</title>
            <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>FF 100 µg</title>
            <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Rescue Medication Inhalations</title>
          <description>Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).</description>
          <population>ITT Population. The number of participants analyzed depends on the number of participants remaining in the indaicated time period.</population>
          <units>Number of inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-12, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="31.288"/>
                    <measurement group_id="O2" value="7.32" spread="27.667"/>
                    <measurement group_id="O3" value="13.42" spread="43.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-24, n=58, 91, 88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="19.094"/>
                    <measurement group_id="O2" value="6.65" spread="23.257"/>
                    <measurement group_id="O3" value="12.56" spread="54.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-36, n=58, 84, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="36.358"/>
                    <measurement group_id="O2" value="7.45" spread="25.058"/>
                    <measurement group_id="O3" value="14.01" spread="70.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-52, n=57, 79, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="50.851"/>
                    <measurement group_id="O2" value="7.73" spread="22.285"/>
                    <measurement group_id="O3" value="17.78" spread="97.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0-52, n=60, 93, 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.28" spread="132.467"/>
                    <measurement group_id="O2" value="27.13" spread="90.038"/>
                    <measurement group_id="O3" value="56.23" spread="253.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment non-serious adverse events (AEs), defined as those events occurring while participants were on treatment, up to and including the day after the last dose in each treatment period (up to 52 weeks), are reported. SAEs, defined as those events o</time_frame>
      <desc>SAEs and non-serious AEs were collected in the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>FF/GW642444 100/25 µg</title>
          <description>Participants received Fluticasone Furoate (FF)/GW642444 inhalation powder 100/25 micrograms (µg) once daily (OD) in the evening from the Dry Powder Inhalator (DPI) over the 52 week treatment period.</description>
        </group>
        <group group_id="E2">
          <title>FF/GW642444 200/25 µg</title>
          <description>Participants received FF/GW642444 inhalation powder 200/25 µg OD in the evening from the DPI over the 52 week treatment period.</description>
        </group>
        <group group_id="E3">
          <title>FF 100 µg</title>
          <description>Participants received FF inhalation powder 100 µg OD in the evening from the the DPI over the 52 week treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rhinitis hypertrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

